Renal Insufficiency, Chronic  >>  Soliris (eculizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
NCT01567085 / 2010-019631-35: Safety & Efficacy Of Eculizumab In The Prevention Of AMR In Sensitized Recipients Of A Kidney Transplant From A Deceased Donor

Completed
2
80
Europe, RoW
Eculizumab, Soliris
Alexion Pharmaceuticals
Stage V Chronic Kidney Disease
06/15
05/17
NCT01756508: Eculizumab for Prevention and Treatment of Kidney Graft Reperfusion Injury

Completed
2
57
RoW
eculizumab, Soliris
Russian Academy of Medical Sciences
End-Stage Renal Disease, Kidney Failure, Graft Reperfusion Injury
04/17
12/17

Download Options